Pfizer’s Investigational Drug Flunks Late-Stage For Sickle Cell Disease

All NewsAugust 15, 2025

Pfizer’s Phase 3 trial of inclacumab in sickle cell disease misses its main goal but shows safety, with further updates on other drugs planned.

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT

Manage consent